Floatz logo

Pyrotinib

ctDNA

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the ctDNA cohort.

Asset / SponsorPhaseRating
Adebrelimab
M.D. Anderson Cancer Center
Phase 2CCC
FLUOROURACILUM
Fudan University
Phase 2CCC
Calcium folinate pentahydrate
Fudan University
Phase 2CCC
Ivonescimab
Fudan University
Phase 2CCC
Capecitabine
Fudan University
Phase 2CCC

View all 13 →

Same molecule, other indications

Pyrotinib is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
70 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →